The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $1.62 in the prior trading day, Alx Oncology Holdings Inc (NASDAQ: ALXO) closed at $1.44, down -11.11%. In other words, the price has decreased by -$11.11 from its previous closing price. On the day, 0.62 million shares were traded. ALXO stock price reached its highest trading level at $1.6 during the session, while it also had its lowest trading level at $1.42.
Ratios:
Our goal is to gain a better understanding of ALXO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.39 and its Current Ratio is at 4.39. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Stifel on March 08, 2024, Downgraded its rating to Hold and sets its target price to $14 from $10 previously.
On December 08, 2023, Jefferies Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $8 to $18.
Jefferies Downgraded its Buy to Hold on December 22, 2021, whereas the target price for the stock was revised from $65 to $25.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 14 ’24 when Pinto Shelly sold 564 shares for $2.58 per share. The transaction valued at 1,455 led to the insider holds 91,549 shares of the business.
Randolph Sophia sold 1,365 shares of ALXO for $3,522 on Aug 14 ’24. The CHIEF MEDICAL OFFICER now owns 325,711 shares after completing the transaction at $2.58 per share. On Aug 14 ’24, another insider, Pons Jaume, who serves as the PRESIDENT & CSO of the company, sold 1,937 shares for $2.58 each. As a result, the insider received 4,997 and left with 591,510 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALXO now has a Market Capitalization of 75847392 and an Enterprise Value of -63403624.
Stock Price History:
The Beta on a monthly basis for ALXO is 1.01, which has changed by -0.8422782 over the last 52 weeks, in comparison to a change of 0.33556926 over the same period for the S&P500. Over the past 52 weeks, ALXO has reached a high of $17.83, while it has fallen to a 52-week low of $1.56. The 50-Day Moving Average of the stock is -34.92%, while the 200-Day Moving Average is calculated to be -85.18%.
Shares Statistics:
The stock has traded on average 1.15M shares per day over the past 3-months and 469410 shares per day over the last 10 days, according to various share statistics. A total of 49.95M shares are outstanding, with a floating share count of 30.21M. Insiders hold about 42.64% of the company’s shares, while institutions hold 71.68% stake in the company. Shares short for ALXO as of 1727654400 were 9319104 with a Short Ratio of 8.13, compared to 1724976000 on 9978290. Therefore, it implies a Short% of Shares Outstanding of 9319104 and a Short% of Float of 30.69.
Earnings Estimates
A comprehensive evaluation of Alx Oncology Holdings Inc (ALXO) is underway, with the input of 6.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.67 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$2.87 and -$3.23 for the fiscal current year, implying an average EPS of -$3.04. EPS for the following year is -$2.88, with 5.0 analysts recommending between -$2.56 and -$3.41.
